67828-57-3 Usage
Uses
Used in Pharmaceutical Industry:
1-(2-Methoxy-4-nitrophenyl)pyrrolidine is used as a pharmaceutical intermediate for the synthesis of various drugs, especially those targeting the central nervous system. Its unique chemical structure and properties make it a valuable component in the development of new therapeutic agents.
Used in Research and Development:
1-(2-Methoxy-4-nitrophenyl)pyrrolidine is used as a research compound in the pharmaceutical industry to explore its potential therapeutic applications. Its presence in the synthesis of drugs allows researchers to study its effects and interactions with biological systems, contributing to the advancement of drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 67828-57-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,8,2 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 67828-57:
(7*6)+(6*7)+(5*8)+(4*2)+(3*8)+(2*5)+(1*7)=173
173 % 10 = 3
So 67828-57-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H14N2O3/c1-16-11-8-9(13(14)15)4-5-10(11)12-6-2-3-7-12/h4-5,8H,2-3,6-7H2,1H3
67828-57-3Relevant academic research and scientific papers
MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
-
Page/Page column 15, (2008/06/13)
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
